Omalizumab, a novel anti-IgE therapy in allergic disorders

Author： Babu K Suresh   Holgate Stephen T   Arshad S Hasan  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.1, Iss.6, 2001-11, pp. : 1049-1058

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapy of allergic bronchial asthma with omalizumab – an anti-IgE monoclonal antibody

By D’Amato Gennaro  

Expert Opinion on Biological Therapy, Vol. 3, Iss. 2, 2003-04 ,pp. : 371-376

Informa Healthcare

Access to resources Recommend Favorite

Anti-IgE – emerging opportunities for Omalizumab

By Babu K Suresh   Polosa Riccardo   Morjaria Jaymin B  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 5, 2013-05 ,pp. : 765-777

Informa Healthcare

Access to resources Recommend Favorite

Anti-IgE in allergic asthma and rhinitis: an update

By Morjaria Jaymin B   Gnanakumaran Gnanasekaran   Babu Kesavan Suresh  

Expert Opinion on Biological Therapy, Vol. 7, Iss. 11, 2007-11 ,pp. : 1739-1747

Informa Healthcare

Access to resources Recommend Favorite

Omalizumab for treatment of allergic rhinitis

By Vashisht Priyanka  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 6, 2013-08 ,pp. : 933-945

Informa Healthcare

Access to resources Recommend Favorite

IgE-Anti-IgE-Induced Prostaglandin D 2 Release from Cultured Human Mast Cells

By Obata T.   Nagakura T.   Kanbe M.   Masaki T.   Maekawa K.   Yamashita K.  

Biochemical and Biophysical Research Communications, Vol. 225, Iss. 3, 1996-08 ,pp. : 1015-1020

Elsevier

Access to resources Recommend Favorite